Jun 02, 2026 7:00am EDT Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson’s RAS Signaling Inhibition Mechanism
May 18, 2026 7:00am EDT Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market
May 13, 2026 7:00am EDT Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy
Apr 30, 2026 8:31am EDT Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months
Mar 30, 2026 7:20am EDT Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026
Mar 26, 2026 9:27am EDT Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient
Mar 17, 2026 7:47am EDT Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance
Mar 04, 2026 10:25am EST Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
Mar 04, 2026 7:00am EST Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study
Feb 17, 2026 7:00am EST Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson
